Chemokine Levels among Patients with Middle East Respiratory Syndrome Coronavirus Infection

• Published in: Vaccines (Basel) Vol. 11; no. 6; p. 1048
• Main Authors: Alhetheel, Abdulkarim, Albarrag, Ahmed, Shakoor, Zahid, Somily, Ali, Barry, Mazin, Altalhi, Haifa, Bakhrebah, Muhammed, Nassar, Majed, Alfageeh, Mohamed, Assiri, Ayed, Alfaraj, Sarah, Memish, Ziad
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.05.2023; MDPI
• Subjects: Analysis; Cell activation; Chemokines; Coronaviruses; COVID-19; Disease transmission; Eotaxin; Health aspects; Inflammation; Interferon; Interferon-inducible protein; Interleukin 8; IP-10 protein; Lymphocytes; Lymphocytes T; Macrophage inflammatory protein; Macrophage inflammatory protein 1; MERS-CoV; Middle East respiratory syndrome; Monocyte chemoattractant protein; Monocyte chemoattractant protein 1; Monocytes; Morbidity; Mortality; Plasma levels; Proteins; RANTES; Respiratory diseases; Saudi Arabia; γ-Interferon; Middle East; United States > US; Saudi Arabia; chemokines; MERS-CoV
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11061048

Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant morbidity and mortality due to intense pulmonary inflammation. Enhanced chemokine-mediated leukocyte infiltration in lungs has been linked with unfavorable outcomes with respect to the disease. This cross-sectional study assessed the levels of chemokines among 46 MERS-CoV-infected patients (19 asymptomatic and 27 symptomatic) and 52 healthy controls using a customized Luminex human chemokine magnetic multiplex panel. The plasma levels of interferon-inducible protein (IP)-10 (568.5 ± 114.7 vs. 55.19 ± 5.85 pg/mL; < 0.0001), macrophage inflammatory protein (MIP)-1 alpha (MIP-1A) (30.78 ± 2.81 vs. 18.16 ± 0.91 pg/mL; < 0.0001), MIP-1B (36.63 ± 4.25 vs. 25.26 ± 1.51 pg/mL; < 0.003), monocyte chemoattractant protein (MCP)-1 (1267 ± 309.5 vs. 390.0 ± 35.51 pg/mL; < 0.0002), and monokine-induced gamma interferon (MIG) (28.96 ± 3.93 vs. 16.29 ± 1.69 pg/mL; < 0.001), interleukin (IL)-8 (147.9 ± 21.57 vs. 84.63 ± 10.62 pg/mL; < 0.004) were significantly higher in symptomatic patients than healthy controls. Likewise, the levels of IP-10 (247.6 ± 80.09 vs. 55.19 ± 5.85 pg/mL; < 0.0002) and MCP-1 (650.7 ± 149 pg/mL vs. 390 ± 35.51 pg/mL; < 0.02) were also significantly higher in asymptomatic patients compared to healthy controls. However, no differences were observed in the plasma levels of MIP-1A, MIP-1B, MIG, and IL-8 between asymptomatic patients and uninfected controls. Conversely, the mean plasma levels of regulated on activation normal T cell expressed and secreted (RANTES) (3039 ± 301.0 vs. 4390 ± 223 pg/mL; < 0.001) and eotaxin (176.9 ± 30.20 vs. 296.2 ± 28.11 pg/mL; < 0.01) were significantly lower in symptomatic MERS-CoV-infected patients compared to healthy controls. Likewise, the levels of eotaxin (162.7 ± 21.60 vs. 296.2 ± 28.11 pg/mL; < 0.01) were also significantly lower in asymptomatic patients. Interestingly, the level of MCP-1 (2139 ± 548.2 vs. 776.5 ± 165.3 pg/mL; < 0.004) was significantly higher in deceased symptomatic patients compared to recovered symptomatic patients. MCP-1 was the only chemokine associated with a higher risk of mortality. Symptomatic MERS-CoV-infected patients had a significant elevation of plasma chemokines and elevated MCP-1 levels were found to be associated with fatal outcomes.